Literature DB >> 18434215

PIIANP and HELIXII diurnal variation.

D J Quintana1, P Garnero, J L Huebner, N Charni-Ben Tabassi, V B Kraus.   

Abstract

OBJECTIVE: Serum levels of procollagen type IIA N-terminal propeptide (sPIIANP) and type-II collagen helical peptide (sHELIXII) biomarkers were evaluated for variation diurnally and with physical activity and food in participants with osteoarthritis (OA) of the knee.
METHODS: Forty participants with OA of at least one knee were admitted overnight to the General Clinical Research Center for serial serum sampling. Samples were obtained on the evening (6-8 pm) of Day 1 (T3, n=40); prior to rising (8 am) from bed (T0, n=40); 1 h after rising (9 am) without food consumption (T1a, n=20); 1-2 h after rising (9-10 am) with food consumption (T1, n=40); and additionally at noon, 4 h after rising (T2, n=20). sPIIANP and sHELIXII were measured by enzyme-linked immunosorbent assay. Results were analyzed using non-parametric Freidman's test with Dunn's post-hoc multiple comparison test.
RESULTS: Normalized mean concentrations for sPIIANP and sHELIXII increased significantly from T0 to T1 (P<0.05).
CONCLUSIONS: This is the first study to demonstrate diurnal variation of these collagen-II biomarkers in individuals with knee OA. These results suggest that serum sampling for these markers should be standardized for purposes of clinical trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18434215      PMCID: PMC3666849          DOI: 10.1016/j.joca.2008.03.006

Source DB:  PubMed          Journal:  Osteoarthritis Cartilage        ISSN: 1063-4584            Impact factor:   6.576


  14 in total

1.  Variation of serum hyaluronan with activity in individuals with knee osteoarthritis.

Authors:  Lisa G Criscione; Alan L Elliott; Thomas Stabler; Joanne M Jordan; Carl F Pieper; Virginia B Kraus
Journal:  Osteoarthritis Cartilage       Date:  2005-09       Impact factor: 6.576

2.  Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.

Authors:  Nadine Charni; Fabrice Juillet; Patrick Garnero
Journal:  Arthritis Rheum       Date:  2005-04

3.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

4.  Glucosamine sulfate and cartilage type II collagen degradation in patients with knee osteoarthritis: randomized discontinuation trial results employing biomarkers.

Authors:  Jolanda Cibere; Anona Thorne; Jacek A Kopec; Joel Singer; Janice Canvin; David B Robinson; Janet Pope; Paul Hong; Eric Grant; Tatiana Lobanok; Mirela Ionescu; A Robin Poole; John M Esdaile
Journal:  J Rheumatol       Date:  2005-05       Impact factor: 4.666

5.  Reexpression of type IIA procollagen by adult articular chondrocytes in osteoarthritic cartilage.

Authors:  T Aigner; Y Zhu; H H Chansky; F A Matsen; W J Maloney; L J Sandell
Journal:  Arthritis Rheum       Date:  1999-07

6.  Serum levels of hyaluronan, antigenic keratan sulfate, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 change predictably in rheumatoid arthritis patients who have begun activity after a night of bed rest.

Authors:  D H Manicourt; P Poilvache; A Nzeusseu; A van Egeren; J P Devogelaer; M E Lenz; E J Thonar
Journal:  Arthritis Rheum       Date:  1999-09

7.  Differential expression of a cysteine-rich domain in the amino-terminal propeptide of type II (cartilage) procollagen by alternative splicing of mRNA.

Authors:  M C Ryan; L J Sandell
Journal:  J Biol Chem       Date:  1990-06-25       Impact factor: 5.157

8.  Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate.

Authors:  S Christgau; Y Henrotin; L B Tankó; L C Rovati; J Collette; O Bruyere; R Deroisy; J Y Reginster
Journal:  Clin Exp Rheumatol       Date:  2004 Jan-Feb       Impact factor: 4.473

9.  Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis.

Authors:  J-C Rousseau; Y Zhu; P Miossec; E Vignon; L J Sandell; P Garnero; P D Delmas
Journal:  Osteoarthritis Cartilage       Date:  2004-06       Impact factor: 6.576

10.  The diurnal variation of serum hyaluronan in health and disease.

Authors:  U Lindqvist; A Engström-Laurent; U Laurent; A Nyberg; U Björklund; H Eriksson; R Pettersson; A Tengblad
Journal:  Scand J Clin Lab Invest       Date:  1988-12       Impact factor: 1.713

View more
  10 in total

Review 1.  Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure.

Authors:  Morten A Karsdal; Mette J Nielsen; Jannie M Sand; Kim Henriksen; Federica Genovese; Anne-Christine Bay-Jensen; Victoria Smith; Joanne I Adamkewicz; Claus Christiansen; Diana J Leeming
Journal:  Assay Drug Dev Technol       Date:  2012-10-09       Impact factor: 1.738

Review 2.  The future of blood-based biomarkers for Alzheimer's disease.

Authors:  Kim Henriksen; Sid E O'Bryant; Harald Hampel; John Q Trojanowski; Thomas J Montine; Andreas Jeromin; Kaj Blennow; Anders Lönneborg; Tony Wyss-Coray; Holly Soares; Chantal Bazenet; Magnus Sjögren; William Hu; Simon Lovestone; Morten A Karsdal; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2013-07-11       Impact factor: 21.566

3.  Recombinant platelet derived growth factor-BB and hyaluronic acid effect in rat osteoarthritis models.

Authors:  I Gusti Ngurah Yudhi Setiawan; I Ketut Suyasa; Putu Astawa; I Wayan Suryanto Dusak; I Ketut Siki Kawiyana; I Gusti Ngurah Wien Aryana
Journal:  J Orthop       Date:  2019-03-02

4.  Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis.

Authors:  V B Kraus; B Burnett; J Coindreau; S Cottrell; D Eyre; M Gendreau; J Gardiner; P Garnero; J Hardin; Y Henrotin; D Heinegård; A Ko; L S Lohmander; G Matthews; J Menetski; R Moskowitz; S Persiani; A R Poole; J-C Rousseau; M Todman
Journal:  Osteoarthritis Cartilage       Date:  2011-03-23       Impact factor: 6.576

Review 5.  Rhythm disturbance in osteoarthritis.

Authors:  Ze Du; Xuanhe You; Diwei Wu; Shishu Huang; Zongke Zhou
Journal:  Cell Commun Signal       Date:  2022-05-24       Impact factor: 7.525

6.  Identification of α2-macroglobulin as a master inhibitor of cartilage-degrading factors that attenuates the progression of posttraumatic osteoarthritis.

Authors:  Shaowei Wang; Xiaochun Wei; Jingming Zhou; Jing Zhang; Kai Li; Qian Chen; Richard Terek; Braden C Fleming; Mary B Goldring; Michael G Ehrlich; Ge Zhang; Lei Wei
Journal:  Arthritis Rheumatol       Date:  2014-07       Impact factor: 10.995

7.  The Helix-II epitope: a cautionary tale from a cartilage biomarker based on an invalid collagen sequence.

Authors:  D R Eyre; M A Weis
Journal:  Osteoarthritis Cartilage       Date:  2009-03-05       Impact factor: 6.576

8.  Type II collagen fragment HELIX-II is a marker for early cartilage lesions but does not predict the progression of cartilage destruction in human knee joint synovial fluid.

Authors:  Xiaochun Wei; Kun Yin; Pengcui Li; Huan Wang; Juan Ding; Wangping Duan; Lei Wei
Journal:  Rheumatol Int       Date:  2012-01-12       Impact factor: 2.631

Review 9.  Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities.

Authors:  Morten A Karsdal; Thasia Woodworth; Kim Henriksen; Walter P Maksymowych; Harry Genant; Philippe Vergnaud; Claus Christiansen; Tanja Schubert; Per Qvist; Georg Schett; Adam Platt; Anne-Christine Bay-Jensen
Journal:  Arthritis Res Ther       Date:  2011-04-28       Impact factor: 5.156

10.  Serum Levels of Coll2-1, a Specific Biomarker of Cartilage Degradation, Are Not Affected by Sampling Conditions, Circadian Rhythm, and Seasonality.

Authors:  Anne-Christine Hick; Misch Fonck; Bérénice Costes; Elisabeth Cobraiville; Sébastien Pirson; Laetitia Garcia; Alain Labasse; Steven Vander Poelen; Yves Henrotin
Journal:  Cartilage       Date:  2019-10-20       Impact factor: 3.117

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.